New hope for aggressive lung cancer: trial tests Triple-Threat treatment
NCT ID NCT07425795
Summary
This study is testing whether adding a new immunotherapy drug (tislelizumab) to standard chemotherapy, followed by targeted chest radiation, can better control advanced small cell lung cancer. The trial will enroll 36 newly diagnosed patients to see if this combination helps keep the cancer from growing longer than current treatments. Patients will receive the immunotherapy along with chemotherapy for 4-6 cycles, then radiation if they respond, followed by ongoing immunotherapy for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Affiliated Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.